Journal Scans
Skin Tumors Induced by Sorafenib; Paradoxical RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53 and TGFBR1
Mechanism of Sorafenib-Induced Skin Tumors Proposed
JP Arnault, C Mateus, B Escudier, G Tomasic, J Wechsler, E Hollville, J-C Soria, D Malka, A Sarasin, M Larcher, J Andree, N Kamsu-Kom, L Boussemart, L Lacroix, A Spatz, A Eggermont, S Druilenec, S Vagner, A Eychene, N Dumaz, C Robert
Yes
20111017
2011 Nov 17
Clin Cancer Res
Skin Tumors Induced by Sorafenib; Paradoxical RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53 and TGFBR1
Clin Cancer Res. 2011 Nov 17;[Epub Ahead of Print], JP Arnault, C Mateus, B Escudier, G Tomasic, J Wechsler, E Hollville, J-C Soria, D Malka, A Sarasin, M Larcher, J Andree, N Kamsu-Kom, L Boussemart, L Lacroix, A Spatz, A Eggermont, S Druilenec, S Vagner, A Eychene, N Dumaz, C Robert
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
The reversible pan-RAF inhibitor sorafenib, as well as two selective BRAF inhibitors, have been associated with the emergence of skin tumors. Sorafenib is used to treat metastatic renal carcinoma and advanced hepatocellular carcinoma. Some 6% to 7% of patients on sorafenib develop borderline cutaneous keratoacanthomas (KA) and squamous cell carcinomas (SCC) during treatment. It seems paradoxical that such skin lesions would occur while patients were receiving an antiproliferative agent.Arnault et...
